Metastatic Castration-resistant Prostate Cancer (mCRPC)

Oncology
3
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
2
AAA617Phase 21 trial
[177Lu]Lu-PSMA-617Phase 21 trial
Active Trials
NCT06004661Recruiting20Est. Jun 2026
NCT05670106Active Not Recruiting62Est. Jun 2026
MediLink Therapeutics
MediLink TherapeuticsChina - Suzhou
1 program
1
YL201 for InjectionPhase 21 trial
Active Trials
NCT06241846RecruitingEst. Feb 2029

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
NovartisAAA617
MediLink TherapeuticsYL201 for Injection
Novartis[177Lu]Lu-PSMA-617

Clinical Trials (3)

Total enrollment: 82 patients across 3 trials

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Start: Apr 2024Est. completion: Jun 202620 patients
Phase 2Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Start: Feb 2024Est. completion: Feb 2029
Phase 2Recruiting
NCT05670106Novartis[177Lu]Lu-PSMA-617

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Start: May 2023Est. completion: Jun 202662 patients
Phase 2Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 82 patients
2 companies competing in this space